Intuitive Surgical (NASDAQ:ISRG) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Posted by Stanley Muller on Oct 21st, 2026

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) had its target price increased by analysts at Robert W. Baird from $513.00 to $550.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Robert W. Baird’s price target would suggest a potential upside of 25.57% from the company’s current price.

Several other equities research analysts have also commented on ISRG. BTIG Research decreased their price objective on shares of Intuitive Surgical from $469.00 to $454.00 and set a “buy” rating for the company in a research note on Monday, October 12th. Citigroup dropped their target price on shares of Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating on the stock in a research report on Friday, July 17th. UBS Group restated a “buy” rating on shares of Intuitive Surgical in a research note on Tuesday, October 13th. Barclays reaffirmed an “overweight” rating and issued a $500.00 target price on shares of Intuitive Surgical in a report on Wednesday. Finally, Erste Group Bank raised Intuitive Surgical from a “hold” rating to a “buy” rating in a research report on Wednesday. Twenty-five research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $501.13.

Check Out Our Latest Stock Report on Intuitive Surgical

Intuitive Surgical Price Performance

ISRG opened at $438.00 on Wednesday. The company has a market capitalization of $154.74 billion, a price-to-earnings ratio of 50.17, a P/E/G ratio of 3.27 and a beta of 1.46. The firm’s fifty day moving average price is $392.96 and its two-hundred day moving average price is $409.06. Intuitive Surgical has a 1 year low of $328.57 and a 1 year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last posted its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same quarter in the prior year, the business posted $2.40 EPS. The business’s revenue was up 21.7% compared to the same quarter last year. As a group, equities analysts anticipate that Intuitive Surgical will post 8.87 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, Director Gary S. Guthart sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $400.00, for a total value of $4,000,000.00. Following the transaction, the director directly owned 1,245,679 shares in the company, valued at $498,271,600. The trade was a 0.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 1,089 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $374.44, for a total transaction of $407,765.16. Following the transaction, the vice president directly owned 1,026 shares of the company’s stock, valued at $384,175.44. This represents a 51.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 12,370 shares of company stock valued at $4,891,989 in the last three months. 0.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Intuitive Surgical

A number of hedge funds have recently modified their holdings of the stock. 3Chopt Investment Partners LLC increased its position in Intuitive Surgical by 5.2% in the first quarter. 3Chopt Investment Partners LLC now owns 462 shares of the medical equipment provider’s stock worth $213,000 after buying an additional 23 shares during the last quarter. Vermillion Wealth Management Inc. raised its stake in shares of Intuitive Surgical by 58.1% in the first quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 25 shares during the period. W.G. Shaheen & Associates DBA Whitney & Co lifted its position in shares of Intuitive Surgical by 1.0% during the 1st quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 2,542 shares of the medical equipment provider’s stock valued at $1,172,000 after buying an additional 25 shares during the last quarter. Blue Fin Capital Inc. lifted its position in shares of Intuitive Surgical by 0.5% during the 1st quarter. Blue Fin Capital Inc. now owns 4,794 shares of the medical equipment provider’s stock valued at $2,210,000 after buying an additional 25 shares during the last quarter. Finally, Red Spruce Capital LLC lifted its position in shares of Intuitive Surgical by 4.1% during the 2nd quarter. Red Spruce Capital LLC now owns 640 shares of the medical equipment provider’s stock valued at $255,000 after buying an additional 25 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

Positive Sentiment: Q3 results exceeded expectations: Revenue rose 21.7% year over year to $3.05 billion, above the approximately $2.91 billion consensus, while adjusted earnings reached $3.00 per share versus estimates of roughly $2.61–$2.65. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
Positive Sentiment: Underlying demand remained healthy: Worldwide procedures increased approximately 15%, including 14% growth for da Vinci procedures and 31% for Ion procedures. Intuitive placed 546 robotic systems, up from 427 a year earlier. Intuitive Announces Third Quarter Earnings
Positive Sentiment: Potentially broader adoption: Intuitive plans to extend instrument life and reduce per-procedure costs in 2027. Although this could pressure near-term revenue per procedure, management views it as a way to make robotic surgery more affordable and expand the installed base. Why ISRG Is Lowering Instrument Costs Despite Strong Profitability
Neutral Sentiment: Leasing is supporting placements: Operating leases represented 54% of second-quarter da Vinci placements, up from 49% a year earlier. Leasing may accelerate hospital adoption, but it can also make Intuitive’s returns more dependent on future procedure volume. Does Leasing Make Growth More Durable or More Capital Intensive?
Negative Sentiment: Large antitrust settlement charge hurt GAAP earnings: Intuitive recorded a $450 million pre-tax charge, or $347 million after tax, related to a proposed settlement. GAAP net income fell to $523 million, or $1.49 per share, from $704 million, or $1.95 per share, a year earlier; court approval is still required. Antitrust Settlement Charge Overshadows Strong Q3 Growth
Negative Sentiment: 2026 procedure-growth guidance was narrowed to 14%–15%: The tighter outlook, along with planned pricing actions targeting a 3%–5% reduction in instrument and accessory costs per procedure, raised concerns that growth and margins may moderate. Intuitive Narrows 2026 Procedure Growth Outlook

About Intuitive Surgical

(Get Free Report)

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.